Matches in SemOpenAlex for { <https://semopenalex.org/work/W61670525> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W61670525 endingPage "8" @default.
- W61670525 startingPage "145" @default.
- W61670525 abstract "To demonstrate the pharmacokinetic profile of meropenem when administered by 3-hour infusion in patients undergoing continuous veno-venous hemofiltration (CVVH).The study was conducted in 10 patients, who were treated with CVVH. Each subject received meropenem in 3-hour infusion of 500 mg every 6 hours. Blood samples were collected before infusion (0 hour) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6 hours (just before the infusion of the next dose) after the beginning of the fourth infusion. The concentrations of meropenem in plasma were measured by high-performance liquid chromatography method, and mean serum meropenem concentration-time curve was plotted.Peak plasma drug concentrations measured 3 hours post-infusion were (25.05 ± 5.64) mg/L, and trough levels after 6 hours of infusion were (13.03 ± 3.01) mg/L. The area under the plasma concentration-time curve (AUC) was (118.42 ± 26.78) mg x h⁻¹ x L⁻². The elimination half-life (T1/2) was (3.74 ± 0.55) hours. The mean residence time (MRT) was (4.99 ± 0.84) hours. The volume of distribution (Vb) was (22.85 ± 9.85) L and clearance of meropenem (CL) was (4.49 ± 1.32) L/h. The percentage of time that the serum drug concentration was above the minimum inhibitory concentration (MIC) accounting for the interval time of infusion (%T>MIC) was 100% (MIC 8 mg/L) in all the 10 patients.Based on these data, we concluded that satisfactory pharmacodynamic parameters could be attained in CVVH patients treated with meropenem by a prolonged infusion time of 3 hours with a dosage of 500 mg for every 6 hours." @default.
- W61670525 created "2016-06-24" @default.
- W61670525 creator A5001856496 @default.
- W61670525 creator A5003928525 @default.
- W61670525 creator A5014244832 @default.
- W61670525 creator A5042393602 @default.
- W61670525 creator A5050475802 @default.
- W61670525 creator A5053120081 @default.
- W61670525 creator A5054373322 @default.
- W61670525 creator A5068136904 @default.
- W61670525 creator A5075096356 @default.
- W61670525 creator A5077165659 @default.
- W61670525 date "2012-03-01" @default.
- W61670525 modified "2023-09-26" @default.
- W61670525 title "[Pharmacokinetics of meropenem administered with prolonged infusion time in patients receiving continuous veno-venous hemofiltration]." @default.
- W61670525 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22401158" @default.
- W61670525 hasPublicationYear "2012" @default.
- W61670525 type Work @default.
- W61670525 sameAs 61670525 @default.
- W61670525 citedByCount "0" @default.
- W61670525 crossrefType "journal-article" @default.
- W61670525 hasAuthorship W61670525A5001856496 @default.
- W61670525 hasAuthorship W61670525A5003928525 @default.
- W61670525 hasAuthorship W61670525A5014244832 @default.
- W61670525 hasAuthorship W61670525A5042393602 @default.
- W61670525 hasAuthorship W61670525A5050475802 @default.
- W61670525 hasAuthorship W61670525A5053120081 @default.
- W61670525 hasAuthorship W61670525A5054373322 @default.
- W61670525 hasAuthorship W61670525A5068136904 @default.
- W61670525 hasAuthorship W61670525A5075096356 @default.
- W61670525 hasAuthorship W61670525A5077165659 @default.
- W61670525 hasConcept C111113717 @default.
- W61670525 hasConcept C112705442 @default.
- W61670525 hasConcept C126322002 @default.
- W61670525 hasConcept C126894567 @default.
- W61670525 hasConcept C139254425 @default.
- W61670525 hasConcept C141071460 @default.
- W61670525 hasConcept C2778063415 @default.
- W61670525 hasConcept C2778865887 @default.
- W61670525 hasConcept C2779375183 @default.
- W61670525 hasConcept C2910800852 @default.
- W61670525 hasConcept C42219234 @default.
- W61670525 hasConcept C43044207 @default.
- W61670525 hasConcept C501593827 @default.
- W61670525 hasConcept C71924100 @default.
- W61670525 hasConcept C86803240 @default.
- W61670525 hasConcept C89423630 @default.
- W61670525 hasConcept C94665300 @default.
- W61670525 hasConcept C98274493 @default.
- W61670525 hasConceptScore W61670525C111113717 @default.
- W61670525 hasConceptScore W61670525C112705442 @default.
- W61670525 hasConceptScore W61670525C126322002 @default.
- W61670525 hasConceptScore W61670525C126894567 @default.
- W61670525 hasConceptScore W61670525C139254425 @default.
- W61670525 hasConceptScore W61670525C141071460 @default.
- W61670525 hasConceptScore W61670525C2778063415 @default.
- W61670525 hasConceptScore W61670525C2778865887 @default.
- W61670525 hasConceptScore W61670525C2779375183 @default.
- W61670525 hasConceptScore W61670525C2910800852 @default.
- W61670525 hasConceptScore W61670525C42219234 @default.
- W61670525 hasConceptScore W61670525C43044207 @default.
- W61670525 hasConceptScore W61670525C501593827 @default.
- W61670525 hasConceptScore W61670525C71924100 @default.
- W61670525 hasConceptScore W61670525C86803240 @default.
- W61670525 hasConceptScore W61670525C89423630 @default.
- W61670525 hasConceptScore W61670525C94665300 @default.
- W61670525 hasConceptScore W61670525C98274493 @default.
- W61670525 hasIssue "3" @default.
- W61670525 hasLocation W616705251 @default.
- W61670525 hasOpenAccess W61670525 @default.
- W61670525 hasPrimaryLocation W616705251 @default.
- W61670525 hasRelatedWork W1972377682 @default.
- W61670525 hasRelatedWork W2032781000 @default.
- W61670525 hasRelatedWork W2079711724 @default.
- W61670525 hasRelatedWork W2105898693 @default.
- W61670525 hasRelatedWork W2116637970 @default.
- W61670525 hasRelatedWork W2122724068 @default.
- W61670525 hasRelatedWork W2130905969 @default.
- W61670525 hasRelatedWork W2163514148 @default.
- W61670525 hasRelatedWork W3163678818 @default.
- W61670525 hasRelatedWork W61670525 @default.
- W61670525 hasVolume "24" @default.
- W61670525 isParatext "false" @default.
- W61670525 isRetracted "false" @default.
- W61670525 magId "61670525" @default.
- W61670525 workType "article" @default.